The Tirzepatide + 5-Amino-1MQ stack pairs the most effective dual incretin agonist with a novel NNMT inhibitor for a multi-pathway approach to fat loss. Tirzepatide activates both GIP and GLP-1 receptors, producing superior appetite suppression and metabolic improvement compared to single-incretin agents. 5-Amino-1MQ inhibits NNMT, an enzyme that contributes to fat cell expansion and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ increases NAD+ levels in adipose tissue, boosts cellular energy expenditure, and shrinks fat cells. Together, these compounds create powerful synergy: reduced caloric intake plus enhanced fat cell metabolism.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that outperforms single-incretin agents in clinical trials (SURPASS/SURMOUNT). It produces up to 22.5% body weight reduction by suppressing appetite, slowing gastric emptying, and profoundly improving insulin sensitivity. The dual receptor activation provides metabolic benefits beyond GLP-1-only agents.
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme upregulated in obesity that depletes NAD+ in fat cells and promotes adipocyte expansion. By blocking NNMT, this compound increases cellular NAD+, activates SIRT1 pathways in fat tissue, and increases fat cell energy expenditure. While tirzepatide reduces intake, 5-Amino-1MQ makes each fat cell burn more energy.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | Tirz 2.5mg/wk (wk1-4), 5mg (wk5-8), 7.5mg (wk9+) | 5-Amino 100mg 2x/day oral | AM/PM | 12-16 weeks |
| Aggressive | Tirz titrate to 15mg/wk | 5-Amino 150mg 2x/day | AM/PM | 16 weeks |
| Maintenance | Tirz 5mg/wk | 5-Amino 100mg 1x/day | AM | 8-12 weeks |
| Panel | Markers | Timing |
|---|---|---|
| Metabolic | Fasting glucose, HbA1c, fasting insulin | Baseline, Week 8, Week 16 |
| Lipid | Total cholesterol, LDL, HDL, triglycerides | Baseline, Week 8 |
| Liver | ALT, AST, GGT | Baseline, Week 8 |
| Kidney | BUN, creatinine, eGFR | Baseline, Week 12 |
Tirzepatide significantly improves glycemic markers. Monitor liver function as both compounds undergo hepatic processing.
Start tirzepatide at 2.5mg weekly for 4 weeks, then increase to 5mg for weeks 5-8, then 7.5mg for weeks 9-12. Further titration to 10-15mg is possible based on tolerance. Never skip titration steps to avoid severe GI side effects.
Both compounds work through different pathways with no known direct interactions. 5-Amino-1MQ is an oral NNMT inhibitor while Tirzepatide is an injectable incretin mimetic. However, 5-Amino-1MQ has limited long-term human safety data, so monitoring liver and kidney function is recommended.
Tirzepatide acts as a dual GIP/GLP-1 receptor agonist that powerfully suppresses appetite and improves insulin sensitivity. 5-Amino-1MQ inhibits NNMT enzyme in fat cells, increasing NAD+ levels and boosting adipocyte energy expenditure. Together they reduce caloric intake while simultaneously increasing fat cell metabolism.
Start tirzepatide at 2.5mg weekly for 4 weeks, then increase to 5mg for weeks 5-8, then 7.5mg for weeks 9-12. Further titration to 10-15mg is possible based on tolerance. Never skip titration steps to avoid severe GI side effects.
Both compounds work through different pathways with no known direct interactions. 5-Amino-1MQ is an oral NNMT inhibitor while Tirzepatide is an injectable incretin mimetic. However, 5-Amino-1MQ has limited long-term human safety data, so monitoring liver and kidney function is recommended.
Tirzepatide acts as a dual GIP/GLP-1 receptor agonist that powerfully suppresses appetite and improves insulin sensitivity. 5-Amino-1MQ inhibits NNMT enzyme in fat cells, increasing NAD+ levels and boosting adipocyte energy expenditure. Together they reduce caloric intake while simultaneously increasing fat cell metabolism.
Start tirzepatide at 2.5mg weekly for 4 weeks, then increase to 5mg for weeks 5-8, then 7.5mg for weeks 9-12. Further titration to 10-15mg is possible based on tolerance. Never skip titration steps to avoid severe GI side effects.
Both compounds work through different pathways with no known direct interactions. 5-Amino-1MQ is an oral NNMT inhibitor while Tirzepatide is an injectable incretin mimetic. However, 5-Amino-1MQ has limited long-term human safety data, so monitoring liver and kidney function is recommended.